Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...

The CHMP has recommended approval of sparsentan for the treatment of primary IgAN – a rare kidney disorder and a leading cause of kidney failure – in adults with a urine protein excretion ...

It has not been established whether Vanrafia slows kidney function decline in patients with IgAN. The company noted that the continued approval of Vanrafia may be contingent upon the verification ...